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Abstract 
Body concealment is an important component of appearance distress for individuals with 
disfiguring conditions, including scleroderma. The objective was to replicate the validation study 
of the Body Concealment Scale for Scleroderma (BCSS) among 897 scleroderma patients. The 
factor structure of the BCSS was evaluated using confirmatory factor analysis and the Multiple-
Indicator Multiple-Cause model examined differential item functioning of SWAP items for sex 
and age. Internal consistency reliability was assessed via Cronbach’s alpha. Construct validity 
was assessed by comparing the BCSS with a measure of body image distress and measures of 
mental health and pain intensity. Results replicated the original validation study, where a bifactor 
model provided the best fit. The BCSS demonstrated strong internal consistency reliability and 
construct validity. Findings further support the BCSS as a valid measure of body concealment in 
scleroderma and provide new evidence that scores can be compared and combined across sexes 
and ages. 
 
Keywords: systemic sclerosis, scleroderma, disfigurement, body image avoidance, body 
concealment, measurement  
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Validation of the Body Concealment Scale for Scleroderma (BCSS): 
Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort 
 Systemic sclerosis (SSc), or scleroderma, is a rare, chronic, autoimmune connective 
tissue disease with no known cure. Onset of SSc is highest between the ages of 30-50 years, and 
women are four to five times more likely to be diagnosed with SSc than men (Mayes, 2003). 
Some research suggests that individuals from non-White racial/ethnic backgrounds have higher 
prevalence rates of SSc than White individuals; however, this evidence is limited (Mayes, 2005). 
Disfiguring appearance changes, including hand contractures, digital ulcers, telangiectasia, 
hyper- and hypo-pigmentation of the skin, and altered facial features, are common among many 
SSc patients (Boin & Wigley, 2012). These appearance changes often affect highly visible body 
parts that are important for social interactions, such as the face, mouth, and hands. The 
psychological and psychosocial impact of visible differences experienced by people with SSc 
can be significant, and no treatments alleviate disfiguring disease manifestations. Appearance 
changes in SSc are associated with body image dissatisfaction, poor appearance self-esteem, 
social discomfort, and depressive symptoms (Benrud-Larson et al., 2003; Jewett et al., 2012; van 
Lankveld, Vonk, Teunissen, & van den Hoogen, 2007). 
Among people with visible differences, appearance concerns can generate fear of 
negative evaluation and social anxiety, which, in turn, can lead to avoidance behaviors, such as 
social withdrawal or concealment of body parts (Newell, 1999; Rumsey & Harcourt, 2004). 
Body concealment is used as a coping strategy among many individuals with visible differences. 
People with SSc experience unique appearance changes, particularly skin- and hand-related 
changes; thus, it is important to assess concealment behaviors specific to SSc in order to increase 
understanding about the etiology and consequences of these concerns and to improve the scope 
BODY CONCEALMENT SCALE FOR SCLERODERMA  
 
 
3 
of clinical assessment of such concerns. Jewett et al. (2016) recently developed a brief self-report 
measure, the Body Concealment Scale for Scleroderma (BCSS), to assess disease-specific body 
concealment behaviors related to appearance changes in SSc. The initial validation of the BCSS 
(N = 742) found that a bifactor structure fit best. The BCSS had two identifiable factors 
(Concealment with Clothing and Concealment of Hands), but a general factor explained the 
majority of item covariance, supporting the use of a single total score (Jewett et al., 2016). The 
BCSS total score demonstrated strong internal consistency reliability ( = .88) and good 
construct validity (Jewett et al., 2016).  
All research findings, including those related to measurement, are subject to chance 
findings and should be replicated (Thompson, 2004). Therefore, the first objective of the present 
study was to replicate findings from the initial BCSS validation study in a large, international 
SSc cohort. The second objective was to examine the measurement equivalency of the BCSS 
across sex and age. Measurement equivalency occurs when individuals from different groups 
(e.g., females and males) with similar levels of a construct being measured obtain similar scores 
on the measure and respond similarly to individual items of the measure (Mokkink et al., 2010). 
Differential item functioning (DIF), on the other hand, occurs when an item has different 
measurement properties for one group compared to another, apart from any true differences in 
the construct being measured (Mokkink et al., 2010). DIF is generally evaluated by identifying 
differences in individual item scores across groups that remain present after controlling for levels 
of the overall construct being measured (e.g., body concealment behaviours; Mokkink et al., 
2010). When DIF is present, it is assumed that scores on the item are affected by group 
characteristics that are not directly related to the construct being measured (Mokkink et al., 
2010). Measurement equivalency is a central component of assessing the validity of any 
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measure, and it becomes especially important in the context of rare diseases like SSc, where 
researchers increasingly combine results across groups with distinct characteristics in order to 
attain large enough sample sizes. However, results should only be combined if measurement 
equivalency is established (Mokkink et al., 2010). To date, the measurement equivalency of the 
BCSS has not been established for characteristics that might be expected to influence scores, 
such as age and sex, as it is well documented in the visible difference literature that younger 
individuals and those of the female sex report more body image distress and appearance-related 
concerns (Clarke et al., 2013; Rumsey, Clarke, White, Wyn-Williams, & Garlick, 2004; 
Tiggeman, 2004; Thompson & Kent, 2001).   
Consistent with Jewett et al. (2016), we hypothesized that a bifactor model would provide 
the best fit for the BCSS. Further, we hypothesized that the BCSS total score would correlate 
strongly (i.e., r ≥ .50) with the Brief-Satisfaction with Appearance (Brief-SWAP) Social 
Discomfort subscale score; to a moderate or strong degree (i.e., r  ≥ .30 to ≤ .50) with the Brief-
SWAP Dissatisfaction with Appearance subscale score, Brief Fear of Negative Evaluation 
(BFNE-II) total score, Social Interaction Anxiety Scale (SIAS-6) total score, and the Patient-
Reported Outcomes Measurement Information System (PROMIS-29v2) Health Profile 
depression domain score; and to a small to moderate degree (i.e., r < .30) with the PROMIS-
29v2 pain intensity domain score.  
Method 
Patients and Procedure 
The sample consisted of patients enrolled in the Scleroderma Patient-centered 
Intervention Network (SPIN) Cohort (Kwakkenbos et al., 2013) who completed baseline study 
questionnaires between April 2014 and February 2016. Patients were enrolled at 27 SPIN centers 
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in Canada, the USA, and the UK. To be eligible for the SPIN Cohort, patients must be classified 
as having SSc according to the 2013 American College of Rheumatology/European League 
Against Rheumatism classification criteria (van den Hoogen et al., 2013), be ≥ 18 years of age, 
have the ability to give informed consent, be fluent in English or French, and be able to respond 
to questionnaires via the Internet. The SPIN sample is a convenience sample. Eligible patients 
are invited by physicians or supervised nurse coordinators from SPIN centers to participate in the 
SPIN Cohort, and written informed consent is obtained. Local SPIN physicians or nurse 
coordinators complete an online medical data form to initiate registration. An automated 
welcoming email is sent to participants with instructions for activating their SPIN account and 
completing SPIN Cohort measures. SPIN Cohort patients complete outcome measures via the 
Internet upon enrollment and subsequently every three months (Kwakkenbos et al., 2013). SSc 
patients in the SPIN Cohort who had complete data at their baseline assessment for all BCSS 
items were included in the present analyses. The SPIN Cohort study was approved by the 
Research Ethics Committee of the Jewish General Hospital, Montréal, Canada and by the 
research ethics committees of each participating center. 
Measures  
Sociodemographic information was collected via patient self-report, and disease 
characteristics were obtained from physicians’ reports. Disease duration was defined as years 
since onset of the first non-Raynaud’s Phenomenon symptoms. Limited SSc was defined as skin 
involvement distal to the elbows and knees and diffuse SSc as skin involvement proximal to the 
elbows and knees or the trunk (van den Hoogen et al., 2013).  
Body Concealment Scale for Scleroderma (BCSS). The 9-item BCSS assesses body 
concealment behaviors in SSc (Jewett et al., 2016). BCSS item responses reflect frequency of 
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current behaviors (0 = never to 5 = always). Higher total scores reflect more concealment 
behaviors.  
Brief-Satisfaction with Appearance Scale (Brief-SWAP). The 6-item Brief-SWAP 
(Jewett et al., 2010) assesses body image-related distress in SSc and includes two subscales, 
Dissatisfaction with Appearance and Social Discomfort. Items are scored on a 7-point scale (0 = 
strongly disagree to 6 = strongly agree). Higher scores indicate greater dissatisfaction or social 
discomfort. The Brief-SWAP has strong internal consistency reliability ( = .81 for both 
subscales) and good construct validity (Jewett et al., 2010). In the present study, Cronbach’s 
alpha for the Brief-SWAP Social Discomfort subscale was .88 and was .80 for the Brief-SWAP 
Dissatisfaction with Appearance subscale.  
Brief Fear of Negative Evaluation Scale (BFNE-II). The 12-item BFNE-II assesses 
worry about how one is perceived and evaluated by others (Carleton, Collimore, & Asmundson, 
2007). Items are rated on a 5-point scale (0 = not characteristic of me at all to 4 = extremely 
characteristic of me). Higher summed total scores indicate greater fear of negative evaluation. 
The BNFE-II has good internal consistency reliability and validity (Carleton et al., 2007). In the 
present study, Cronbach’s alpha for the BFNE-II was .97. 
Social Interaction Anxiety Scale (SIAS-6). The 6-item SIAS-6 assesses anxiety from 
social interactions (Peters, Sunderland, Andrews, Rapee, & Mattlick, 2012). Items are scored on 
a 5-point scale (0 = not at all characteristic of me to 4 = extremely characteristic of me). Higher 
summed total scores indicate greater interactional anxiety. The SIAS-6 has strong psychometric 
properties including internal consistency reliability and convergent validity (Peters et al., 2012). 
In the present study, Cronbach’s alpha for the SIAS-6 was .89.   
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Patient-Reported Outcomes Measurement Information System Health Profile 
Depression and Pain Domain Scores (PROMIS-29v2). The PROMIS-29v2 assesses patient-
reported health status on seven domains, including depression (four items scored on a 5-point 
scale ranging from 1 = never to 5 = always), plus a single item for pain intensity (scored on an 
11-point rating scale) (Hinchcliff et al., 2011). Higher scores represent more of the measured 
domain, and raw scores are converted into T-scores standardized based on a general US 
population sample (M = 50, SD = 10) (Hinchcliff et al., 2011). The PROMIS-29v2 has strong 
psychometric properties, including construct validity (Hinchcliff et al., 2011). In the present 
study, Cronbach’s alpha for the PROMIS-29v2 Depression Domain Score was .93 and was .97 
for the Pain Domain Score.   
Data Analysis 
The factor structure of the BCSS was evaluated first in the total sample using 
Confirmatory factor analysis (CFA). Given that in the original BCSS development study, single-
factor, two-factor (Concealment with Clothing and Concealment of Hands), and bifactor models 
were tested, the same three models were replicated in the present study. Bifactor models evaluate 
the degree to which covariance among a set of item responses can be accounted for by a single 
general factor that reflects common variance among all items, plus specific factors reflecting 
additional common variance among clusters of items with similar content (Cook, Kallen, & 
Amtmann, 2009; Reise, Moore, & Haviland, 2010). Bifactor models can also help assess 
multidimensionality and evaluate whether a unit-weighted composite score for a single latent 
trait can be reasonably interpreted, versus creating subscales, in the context of identifiable 
multidimensionality (Cook et al., 2009; Reise et al., 2010). In the bifactor model, all items were 
specified to load on the general factor in addition to their designated specific factor 
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(Concealment with Clothing and Concealment of Hands), and the general and specific factors 
were specified as orthogonal. To assess the contribution of the general and specific factors to 
explaining item covariance, we calculated explained common variance (ECV), the ratio of 
variance explained by the general factor divided by variance explained by the general plus 
specific factors (Reise, 2012). In addition, coefficient omega, a model-based reliability estimate 
analogous to coefficient alpha, was calculated for the general and specific factors to evaluate the 
degree to which the subscales reflected reliable variance beyond variance captured by the general 
factor (Reise, 2012).  
Item responses for the BCSS were modeled as ordinal Likert data, using the weighted 
least squares estimator with a diagonal weight matrix and robust standard errors and a mean- and 
variance-adjusted chi-square statistic with delta parameterization (Muthén & Muthén, 2012). A 
chi-square goodness-of-fit test and three fit indices were used, including the Tucker-Lewis Index 
(TLI; Tucker & Lewis, 1973), Comparative Fit Index (CFI; Bentler, 1990), and Root Mean 
Square Error of Approximation (RMSEA; Steiger, 1990). Since the chi-square test is highly 
sensitive to sample size and can lead to the rejection of well-fitting models, practical fit indices 
were emphasized (Reise, Widaman, & Pugh, 1993). Models with a TLI and CFI close to .95 or 
higher, and a RMSEA close to .06 or lower, are generally representative of good fitting models 
(Hu & Bentler, 1999).  
In order to determine if the BCSS exhibited DIF for female versus male SSc patients and 
for younger versus older patients, the Multiple-Indicator Multiple-Cause (MIMIC) model was 
utilized. MIMIC models for DIF assessment are based on structural equation models, in which 
the group variable (e.g., sex) is added to the basic CFA model as an observed variable. 
Therefore, the base MIMIC model consists of the CFA factor model with the additional direct 
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effect of group on the latent factors, which serves to control for group differences on the level of 
the latent factors (Mokkink et al., 2010). Ideally for DIF assessment, the simplest factor structure 
with reasonable fit is used. 
To assess for potential DIF, the direct effect of group on BCSS items was assessed for 
each item separately, by regressing the items, one at a time, on group (see Figure 1). Each item 
was tested separately to determine if there was statistically significant DIF, which is represented 
by a statistically significant association in the model from group (e.g., sex) to the item, after 
controlling for any differences in the overall level of the latent factor between groups. If 
statistically significant DIF was present for one or more items, the item with the largest 
magnitude of DIF was considered to have DIF, and the link between the group variable (e.g., 
sex) and that item was included in the model. This procedure was then repeated until none of the 
remaining items showed statistically significant DIF. Hommel’s correction for multiple testing 
(Hommel, 1988) was applied to determine items with statistically significant DIF. 
Once all items with significant DIF were identified, the potential magnitude of all DIF 
items was evaluated collectively, by conducting comparisons of the difference on the latent 
factor between groups in the baseline model (not correcting for DIF) and after controlling for 
DIF. The magnitude of this difference was interpreted using Cohen’s effect size suggestions, 
with ≤ .20 SD indicating small, .50 SD indicating moderate, and .80 SD indicating large 
differences (Cohen, 1988). CFA and DIF analyses were conducted using MPlus, Version 7.  
Cronbach’s alpha was computed for the BCSS to assess internal consistency reliability. 
Construct validity was assessed by calculating Pearson’s bivariate correlations of the BCSS total 
score with the Brief-SWAP subscale scores, PROMIS-29v2 depression and pain domain scores, 
and BFNE-II and SIAS-6 total scores. These analyses were conducted using SPSS, Version 20. 
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Because some SSc patients from the SPIN Cohort could have been included in the Canadian 
Scleroderma Research Group (CSRG) Registry sample used in the original BCSS validation 
study, we also calculated the maximum possible patient overlap between the two samples based 
on sites that contribute data to both cohorts. As a sensitivity analysis, we replicated analyses after 
removing patients from CSRG sites who could have possibly been in the SPIN sample, as it was 
not possible to determine patient-by-patient overlap. 
Results 
Sample Characteristics 
Of 943 patients, 897 had complete BCSS item data and were included in present 
analyses. The majority of the sample was female (N = 782, 87%) and White (N = 774, 86%). 
Mean age was 55.4 years (SD = 12.1), and 41% of patients had diffuse SSc, which is a rate 
similar to that seen among SSc patients more generally (Mayes, 2005). See Table 1 for a 
breakdown of all sociodemographic and disease characteristics. There were 214 patients (24%) 
from CSRG sites whose diagnosis was before the date of the initial validation study using CSRG 
data and who could have possibly been in both cohorts.  
Assessment of the Factor Structure (CFA) of the BCSS  
Model fit for the single-factor model was suboptimal (2(27) = 753.32, CFI = .94, TLI = 
.92, RMSEA = .17). Model fit for the two-factor model was substantially better, (2(26) = 
165.27, CFI = .99, TLI = .98, RMSEA = .08). The correlation between the Concealment with 
Clothing and Concealment of Hands latent factors was .75. Model fit was strongest for the 
bifactor model (2(18) = 81.84, CFI = .99, TLI = .99, RMSEA = .06). The ECV was .79. 
Coefficient omega for the Concealment with Clothing subscale was .01 and .34 for the 
Concealment of Hands subscale. See Table 2 for all model fit parameters.  
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Assessment of the Differential Item Functioning (DIF) of the BCSS   
 MIMIC base model. Given that for DIF assessment, the simplest factor structure with 
reasonable fit is used, the base model consisted of the two-factor model of Concealment with 
Clothing and Concealment of Hands. This two-factor model was extended to include direct 
effects of the Concealment with Clothing and Concealment of Hands latent factors on sex 
(female versus male) and age (dichotomized into age bands of less than 60 years, and 61 years 
and older), separately. These age bands were determined based on an assessment of the age 
distribution of the present sample.  
The MIMIC base model for sex and age both demonstrated strong fit, 2(33) = 183.60, p 
< .001, CFI = .99, TLI = .98, RMSEA = .07 and 2(33) = 183.15, p < .001, CFI = .99, TLI = .98, 
RMSEA = .07, respectively. Prior to accounting for DIF, male patients had .57 SD lower latent 
scores than female patients for the Concealment with Clothing factor (95% Confidence Interval 
[CI] -.82 to -.33) and .16 SD lower latent scores than female patients for the Concealment of 
Hands factor (95% CI -.39 to .07). Prior to accounting for DIF, older patients had .22 SD lower 
latent scores than younger patients for the Concealment with Clothing factor (95% CI -.38 to -
.06) and .41 SD lower latent scores than younger patients for the Concealment of Hands factor 
(95% CI -.57 to -.25).  
 DIF assessment. There were no items that demonstrated statistically significant DIF 
based on sex. Three items were identified with statistically significant DIF based on age: items 2, 
(I wear long sleeves to hide skin changes), 3 (I avoid wearing revealing clothes (e.g., bathing 
suits, tank tops, or shorts)), and 8 (I hide my hands so that people don’t see them). More 
specifically, compared to younger patients, older patients had higher scores (more concealment-
related behaviours) than would be expected on items 2 (z = 2.80, p = .005) and 3 (z = 3.65, p < 
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.001), based on their latent levels of the Concealment with Clothing factor. Compared to younger 
patients, older patients had lower scores than would be expected on item 8 (z = -2.87, p = .004), 
based on their latent levels of the Concealment of Hands factor.  
 After correcting for DIF, the difference on the Concealment with Clothing latent factor 
between younger versus older patients increased from -.22 SD (95% CI -.38 to -.06) to -.32 SD 
(95% -.49 to -.15). The difference on the Concealment of Hands latent factor between younger 
versus older patients decreased slightly from -.41 SD (95% CI -.57 to -.25) to -.35 SD (95% CI -
.52 to -.18). Despite the statistically significant DIF found for three BCSS items, the magnitude 
was small (all ≤ .20 SDs) and did not influence scores substantively. Table 3 shows the baseline 
CFA parameters, before assessing for DIF, as well as the DIF-corrected model parameters for 
age.  
Assessment of the Reliability and Validity of the BCSS Total Score 
Cronbach’s alpha for the BCSS total score was .89. Consistent with hypotheses, the 
BCSS total score was strongly correlated with the Brief-SWAP Social Discomfort subscale (r = 
.63) and moderately correlated with the Brief-SWAP Dissatisfaction with Appearance subscale 
(r = 0.44), BFNE-II total score (r = .43), SIAS-6 total score (r = .40), and PROMIS-29v2 
depression domain score (r = .48). The correlation with the PROMIS-29v2 pain intensity score 
was slightly stronger than hypothesized (r = .46).  
When analyses were replicated removing possibly overlapping patients from CSRG sites, 
sociodemographic data, factor analysis results and reliability and validity indices were virtually 
unchanged (see Supplementary Data file linked online to this article). Given this, DIF analyses 
were only run with the main model, including the full sample, as it is reasonable to assume that 
no differences in terms of the measurement equivalency of BCSS items would emerge if 
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overlapping patients were removed.  
Discussion 
Results replicated the initial BCSS validation study (Jewett et al., 2016). The bifactor 
model fit best, with the general factor explaining 79% of item covariance. Reliability indices for 
the specific factors were very low, suggesting that they do not reliably measure substantive 
variance beyond that explained by the general factor (Reise, 2012). Thus, consistent with the 
initial BCSS validation, evidence from the present study supports the use and interpretation of a 
single summed score for the BCSS. Beyond this, BCSS items demonstrated measurement 
equivalency across female and male patients, and while three items had statistically significant 
DIF for younger versus older patients, the magnitude of the differences was small, and the 
influence on scores was negligible. 
The present study also found evidence of good internal consistency reliability and 
construct validity for the BCSS, similar to the initial validation study. As expected, scores on the 
BCSS correlated most strongly with scores on the Brief-SWAP Social Discomfort subscale, and 
this relationship highlights the social implications of the disfiguring appearance changes 
experienced by many SSc patients. The moderate correlation found between the BCSS and Brief-
SWAP Dissatisfaction with Appearance subscale scores is not surprising, because BCSS items 
pertain less to body image dissatisfaction, and more to social and behavioral avoidance. 
Similarly, the moderate correlations found between scores on the BCSS and scores on the 
BFNE-II, SIAS-6, and PROMIS-29v2 depression domain likely reflect that these latter measures 
tap into mental health constructs rather than body image-related avoidance mechanisms.  
Evidence provided in the current study points to the utility of the BCSS as a patient-
reported outcome in programs designed to address body image concerns among people with SSc, 
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with essentially equivalent measurement properties for both female and male patients and those 
of different ages. Currently, there are programs being developed (Kwakkenbos et al., 2013) that 
target disfigurement-related distress and concealment behaviors specific to SSc, building on 
strategies from social interaction skills training and cognitive behavioral therapy (CBT; Bessell 
et al., 2012; Clarke et al., 2014) that have been used more generally among individuals with 
visible differences. The BCSS could be used as an outcome measure to assess body concealment 
behaviors in such programs.   
There are limitations to consider. First, the SPIN Cohort constitutes a convenience 
sample of SSc patients receiving treatment at SPIN centers, and patients at these centers may 
differ from those in other settings. SPIN Cohort patients complete questionnaires online, which 
may further limit the generalizability of findings. Next, the present sample combined both female 
and male patients, and body concealment behaviors may differ by sex. However, there were not 
enough men to examine measurement properties separately by sex. Additionally, the majority of 
our sample (86%) was White; therefore, results may not be generalizable to individuals from 
non-White racial/ethnic backgrounds. Finally, there was overlap between sites that recruited SSc 
patients for the SPIN Cohort and the CSRG Registry used in the original BCSS validation study, 
and it is possible that some patients were included in both. However, even if all patients from 
those sites were enrolled in both studies, the overlap would have been < 25%. The actual amount 
of overlap is likely much smaller because the studies were conducted several years apart. 
Furthermore, results were virtually identical when possibly overlapping patients were excluded.   
In summary, the present study replicated previous findings and provided further evidence 
for the validity of the BCSS by showing that scores can be compared and combined across 
females and males with SSc, and those of different ages without concern that measurement 
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differences may substantially influence results. The BCSS assesses disease-specific concealment 
behaviors related to the unique skin and hand appearance changes experienced by SSc patients 
and highlights body concealment as a pertinent issue for body image and social interactions for 
individuals with the disease. The BCSS can be used as a clinical assessment tool and as a 
patient-reported outcome measure to assess body concealment behaviors among people with 
SSc. 
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Table 1.  
Sociodemographic and Disease Variables for Scleroderma Patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Note. N = 897. Due to missing values: aN = 894; bN = 554; cN = 824.
Sociodemographic Variables   
Age (M, SD)  55.4 (12.1)a 
Female (n, %)  782 (87.2)  
White (n, %)  774 (86.3) 
Years of Formal Education (M, SD)  15.3 (3.2) 
Employed Full or Part-time (n, %)  357 (64.4)b 
Married or Living as Married (n, %)  654 (72.9) 
Disease Variables   
Diffuse Scleroderma (n, %)  366 (40.8) 
Disease Duration in Years (M, SD)  11.6 (8.8)c 
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Table 2.  
Confirmatory Factor Analysis Models and Parameter Estimates for BCSSa 
 
Note. N = 897. aBCSS responses are scored on a 6-point scale ranging from 0-5 (0 = never, 1 = rarely, 2 = sometimes, 3 = often, 4 = usually, 5 = always). bFactor 
loadings are unstandardized, raw factor loadings. cConcealment with Clothing factor. dConcealment of Hands factor. e = Square root of the error variance. Sum 
of error variances = 6.50. ECV (explained common variance) = .79. Coefficient  (omega) = .89. Coefficient H-GEN (omega hierarchical – general = .80. H-
Clothing = .01. H-Hands = .34. PUC (percent of contaminated correlations) = 56%. 
  Single- 
Factor Model 
Two-Factor 
Model 
 Bifactor 
Model 
  
Item M (SD) Factor 
Loadingb 
Factor 
Loading:b 
Clothingc 
Factor 
Loading:b 
Handsd 
Factor 
Loading:b 
General 
Factor 
Loading:b 
Clothingc 
Factor 
Loading:b 
Handsd 
e 
1. I wear clothes I do not like .72 
(1.11) 
 
.69 .72  .75 -.21  .62 
2. I wear long sleeves to hide skin 
changes 
 
.80 
(1.33) 
.86 .88  .84 .23 
 
 .50 
3. I avoid wearing revealing clothes 
(e.g., bathing suits, tank tops, or 
shorts) 
 
1.63 
(1.75) 
.79 .82  .80 .16 
 
 
 .58 
 
4. I wear clothes that hide the 
changes to my skin 
 
1.06 
(1.46) 
.92 .95  .92 .38 
 
 .40 
5. I wear clothes that will divert 
attention from my appearance 
 
.80 
(1.25) 
.82 .86  .89 -.12 
 
 .46 
6. I wear gloves to hide my hands 
 
.81 
(1.28) 
 
.72  .77 .59  .50 .64 
7. I avoid shaking hands with 
people 
 
.92 
(1.37) 
.78  .83 .60  .61 .52 
8. I hide my hands so that people 
don’t see them 
 
.98 
(1.32) 
.83  .89 .68  
 
.56 
 
.47 
9. I avoid directly giving change or 
other items to people 
.69 
(1.22) 
.80  .87 .67  
 
.52 
 
.53 
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Table 3.  
Factor Loadings of the BCSS Concealment with Clothing and Concealment of Hands Latent Factors 
and Influence on the Overall Estimates of Concealment with Clothing and Concealment of Hands 
Latent Factor Scores for Age  
 
Item   Base Modela DIF Corrected Modelb 
 
 Factor Loading 
(95% CI) 
Factor Loading 
(95% CI) 
Concealment with Clothing Latent Factor   
1. I wear clothes I do not like. .72 (.68, .76) .72 (.68, .76) 
2. I wear long sleeves to hide skin changes.  .88 (.86, .90) .88 (.86, .90) 
3. I avoid wearing revealing clothes (e.g., 
bathing suits, tank tops, or shorts).  
.82 (.79, .85) .83 (.80, .86) 
4. I wear clothes that hide the changes to my 
skin. 
.95 (.93, .97) .94 (.92, .96) 
5. I wear clothes that will divert attention 
from my appearance. 
.85 (.82, .88) .85 (.82, .88) 
 
Concealment of Hands Latent Factor  
 
  
6. I wear gloves to hide my hands. .77 (.73, .81) .77 (.73, .81) 
7. I avoid shaking hands with people.  .82 (.79, .85) .82 (.79, .85) 
8. I hide my hands so that people don’t see 
them. 
.89 (.87, .91) .89 (.87, .91) 
9. I avoid directly giving change or other 
items to people. 
.86 (.83, .89) .86 (.83, .89) 
 
Correlation of Concealment with Clothing and 
Concealment of Hands Latent Factors  
 
.75 (.71, .79) 
 
.75 (.71, .79) 
 
Direct Effects on Items Attributable to Age 
  
Item 2. Long sleeves to hide skin changes --- .17 (.05, .29) 
Item 3. Avoid wearing revealing clothes --- .21 (.10, .32) 
Item 8. Hide my hands --- -.17 (-.29, -.05) 
 
Structural Effect of Age on Latent Factors 
  
Age on Concealment with Clothing factor -.22 (-.38, .-06) -.32 (-.49, -.15) 
Age on Concealment of Hands factor -.41 (-.57, -.25) -.35 (-.52, -.18) 
Note. CI = Confidence Interval. aNot corrected for Differential Item Functioning (DIF); bCorrected for 
DIF on items 2, 3, 8.  
 
